ACME Capital is a conviction-driven deep-tech venture firm that backs founders building ahead of market consensus at major platform shifts. It is strongest from Seed through Series B, especially in technically ambitious companies that can translate hard science or frontier engineering into production systems, enterprise deployments, and scalable market positions.
Evaluation weights
How much weight this firm places on each dimension. Totals 100%.
Revenue, growth, and unit economics
Size, timing, and competitive landscape
Founder experience and execution ability
Differentiation and technical quality
- Non-consensus bets over consensus themes
- Hard traction over vanity metrics
- Systems and infrastructure plays over lightweight apps
- Founders who can execute through complexity over pure visionaries
Pitch difficulty
How hard it is to get a meeting and close funding from this firm.
- Funded / yr
- 12Deals closed in a typical year.
- Led / yr
- 6Rounds led in the last 12 months.
- Pitches / yr
- ~780Decks reviewed in a typical year.
- Acceptance rate
- 1.5%Share of pitches that get funded.
Estimated — public data is not fully disclosed.
Why it's hard
- Strong bias toward deep-tech and platform-shift companies excludes most conventional software startups
- Requires decisive, technically credible founders who can execute in complex markets
- Looks for hard proof points like backlog, pilots, or deployments rather than narrative alone
- Avoids incremental or weakly differentiated businesses even in popular categories
ACME is open to backing ambitious frontier companies early, but it is highly discriminating about founder quality, real technical differentiation, and evidence that the company can survive complex operational or regulatory environments. Its preference for non-consensus, category-defining businesses narrows fit significantly even though it invests across multiple stages.
Green flags
What drives a yes for this firm.
- Technically ambitious founders with decisive execution and clear ownership of hard problems
- A company positioned at a real platform shift before broader market consensus forms
- Evidence of real-world traction such as contracted backlog, enterprise pilots, or production deployments
- Defensible systems-level advantage through vertical integration, proprietary tech, or difficult execution
- A credible path to scaling into a large transformative market with plausible strategic or public exit routes
Red flags
What kills deals and gets a fast no.
- Incremental me-too software pitches with little true differentiation
- Reliance on hype metrics instead of evidence of real customer adoption
- Founders who underestimate regulation, manufacturing, procurement, or deployment complexity
- Weak or unclear route to building a large business in a transformative market
- No plausible strategic or public exit pathway despite high capital intensity
How to win
Patterns that lead to successful pitches.
- Frame the company as a platform-shift winner, not a feature-layer startup
- Show concrete proof of traction through contracts, pilots, deployments, or procurement progress
- Demonstrate why the team is uniquely equipped to navigate technical and operational complexity
- Highlight defensibility through vertical integration, proprietary tech, or systems control points
- Present a credible path to scale and a realistic long-term exit outcome
Fund strategy & identity
Who they are and how they operate.
- Primarily invests from Seed to Series B while supporting companies from Pre-Seed through Growth
- Leads a high share of early-stage rounds and writes concentrated initial checks
- Uses opportunity fund capital and SPVs to double down on breakout companies
- Focuses on U.S. companies with a selective allocation to Europe
- Prefers category-defining systems businesses over incremental point solutions
Firm identity
Investment focus
Industries, themes, and typical ARR expectations.
Industries
Investment themes
Typical check by stage
Typical ARR by stage
Investment thesis
Core beliefs and strategy behind their investing approach.
ACME Capital backs deep‑tech founders who are building ahead of market consensus in sectors undergoing platform shifts. Its taxonomy spans Physical AI, Enterprise Intelligence, Frontier Health, Next‑Gen Compute, Aerospace & Defense, and Industrial Systems, translating to AI‑native systems, quantum and analog compute, space and defense hardware, advanced manufacturing, and AI‑enabled health infrastructure. The firm concentrates on Seed to Series B investments in the United States with up to 25 % of capital allocated to European companies, and it can follow winners via an opportunity fund and SPVs. ACME avoids consensus, incremental plays in saturated categories and seeks companies that can move from lab‑validated breakthroughs to real‑world scaled systems. Its core belief is that value is created by teams positioned at technological discontinuities—platform shifts—who pair deep technical capability with decisive execution and distribution.
Decision patterns
How they evaluate and make investment decisions.
ACME Capital invests in founders who are technically ambitious and can execute decisively, especially when their business sits at the edge of a platform‑shift tailwind that most others consider off‑Broadway. The firm looks for vertical integration, hard‑won early traction such as contracted backlogs, enterprise pilots, or production deployments, rather than vanity metrics. Team and execution are weighted heavily, but a credible path to scale within a large, transformative market is required. Deal‑breakers include me‑too incremental software plays lacking defensibility, teams unable to navigate complex regulatory or operational environments, and founders without a clear exit pathway.
Risk appetite
ACME Capital is moderately aggressive and conviction‑driven. It leads roughly 80 % of its early‑stage rounds with $5‑$10 M initial checks and often doubles down on follow‑on investments. The firm is comfortable with high technical and regulatory risk in sectors such as defense, aerospace, next‑gen compute, and frontier health, provided founders can demonstrate verifiable traction like contracts or deployments. Its two‑fund structure (an early‑stage core and an opportunity vehicle) and use of SPVs show a willingness to concentrate capital behind winners while remaining disciplined about outcomes.
Notable investments
Key portfolio companies and why they fit the thesis.
- Arya HealthLeadModular AI agents for healthcare operations match ACME's AI‑enabled frontier health thesis and early‑stage leadership focus.
- CanopyLeadConnected safety and location intelligence for health systems aligns with ACME's industrial/enterprise intelligence and platform‑shift thesis.
- TreonLeadAI‑native maintenance orchestration for industrial assets fits ACME's physical AI and next‑gen manufacturing focus.
- LaurelLeadTime‑automation AI for professional services bridges physical/enterprise intelligence and workflow automation, aligning with ACME’s thesis.
- RegologyLeadAI‑enabled regulatory intelligence platform fits ACME's enterprise software and applied AI investment area.
- SoLo FundsLeadFintech platform innovation matches ACME's business‑model disruption and consumer/financial services focus.
- BraintrustLeadWeb3‑enabled talent marketplace represents a platform‑shift and business‑model innovation that ACME targets.
Co-invested with
Other firms in this catalog who've backed the same companies.
No catalog overlap found yet. Co-investors are derived from each firm's notable investments — connections may surface as more firms are added.
Partners
Full firm roster — key partners, partners, and the wider team.
Key partners
Scott Stanford
Co-Founder and Partner
ACME Capital
Co-Founder and Partner at ACME Capital, with prior experience as a technology investment banker and co-founder of Sherpa Capital and Silicon Foundry.
Hany Nada
Co-Founder and Partner
ACME Capital
Co-Founder and Partner at ACME Capital, previously a co-founder and long-time Managing Partner at GGV Capital.
Alex Fayette
Partner
ACME Capital
Partner at ACME Capital focused on frontier technology companies tackling technically complex problems.
Aike Ho
Partner
ACME Capital
Partner at ACME Capital focused on frontier health, biology infrastructure, and selective consumer investments.
Christian Tang-Jespersen
Partner
ACME Capital
Partner at ACME Capital with more than 20 years of global operating experience scaling technology companies.
Public voice
Notable statements and public positions.
- We back deep‑tech founders who pair technical ambition with decisive execution. We partner the same way. Through every phase, we show up with conviction, craft, and a bias toward forward motion.
- The first call when there’s no playbook. If we wouldn’t make a founder’s memoir, we’re not doing our job.
- the team has focused on a wide variety of startups in what Stanford calls their off‑Broadway strategy.
Similar firms
Firms with overlapping stage and industry focus.
Andreessen Horowitz
0.5%
Founders Fund
1.5%
Upfront Ventures
0.3%